Chapter 21.9
The Effect of Liver Disease on Bone
Juliet Compston,
Juliet Compston
Search for more papers by this authorJuliet Compston,
Juliet Compston
Search for more papers by this authorBook Editor(s):Juan Rodés MD,
Jean-Pierre Benhamou MD,
Andres T. Blei MD,
Jürg Reichen MD,
Mario Rizzetto MD,
Juan Rodés MD
Director General, Hospital Clinic; Professor of Medicine, University of Barcelona, Barcelona, Spain
Search for more papers by this authorJean-Pierre Benhamou MD
Professor of Hepatology, Université Denis Diderot Paris 7, Assistance Publique — Hôpitaux de Paris and Inserm U773, Service d'Hépatologie, Hôpital Beaujon, Clichy, France
Search for more papers by this authorAndres T. Blei MD
Professor of Medicine and Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorJürg Reichen MD
Professor of Medicine, University of Bern; Chief of Hepatology, University Hospital, Bern, Switzerland
Search for more papers by this authorMario Rizzetto MD
Professor of Gastroenterology, University of Turin, Turin, Italy
Search for more papers by this authorFirst published: 18 June 2007
References
- Compston JE (1986) Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. Gut 27, 1073–1090.
- Dolan P Torgerson DJ (2000) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis Int 11, 551–552.
- Cummings SR Melton LJ III (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359, 1761–1767.
- Cooper C Atkinson EJ O'Fallon WM et al. (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Min Res 7, 221–227.
- Marshall D Johnell O Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Lancet 312, 1254–1259.
- WHO Study Group (1994) Assessment of Fracture Risk and its Application to Postmenopausal Osteoporosis. World Health Organization Technical Report Series No. 843. Geneva: WHO.
- Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359, 1929–1936.
- Genant HK Wu CY van Kuijk C et al. (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Min Res 9, 1137–1148.
- Hay JE (2003) Osteoporosis in liver diseases and after liver transplantation. J Hepatol 38, 856–865.
- Leslie WD Bernstein CN Leboff MS (2003) AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125, 941–966.
- Ninkovic M Love S Tom BDM et al. (2001) High prevalence of osteoporosis in patients with chronic liver disease prior to transplantation. Calcif Tissue Int 69, 321–326.
- Crosbie OM Freaney R McKenna MJ et al. (1999) Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease. Calcif Tissue Int 64, 295–300.
- Diamond T Steil D Lunzer M et al. (1990) Osteoporosis and skeletal fractures in chronic liver disease. Gut 31, 82–87.
- Boulton-Jones AJ Fenn RMF West J et al. (2004) Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls. Aliment Pharmacol Ther 20, 551–557.
- Stellon AJ Webb A Compston JE et al. (1987) Low bone turnover state in primary biliary cirrhosis. Hepatology 7, 137–142.
- Stellon AJ Webb A Compston JE (1988) Bone histomorphometry and studies in corticosteroid treated chronic active hepatitis. Gut 29, 378–389.
- Matloff DS Kaplan MM Neer RM et al. (1982) Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 83, 97–102.
- Stellon AJ Webb A Compston JE et al. (1986) Lack of osteomalacia in chronic cholestatic liver disease. Bone 7, 181–185.
- Hodgson SF Dickson ER Eastell R et al. (1993) Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 14, 819–827.
- Diamond T Stiel D Lunzer M et al. (1989) Ethanol reduces bone formation and may cause osteoporosis. Am J Med 86, 282–288.
- Crilly RG Anderson C Hogan D et al. (1988) Bone histomorphometry, bone mass and related parameters in alcoholic males. Calcif Tissue Int 43, 269–276.
- Cuthbert JA Pak CYC Zerwekh JE et al. (1984) Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 4, 1–8.
- Guichelaar M Malinchoc M Sibonga J et al. (2002) Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 36, 895–903.
- Corazza GR Trevisani F Di Stefano M et al. (2000) Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. Dig Dis Sci 45, 1392–1399.
- Fabrega E Orive A Garcia-Suarez C et al. (2005) Osteoprotegerin and RANKL in alcoholic liver disease. Liver Int 25, 305–310.
- Gonzalez-Calvin JL Gallego-Rojo F Fernandez-Perez R et al. (2004) Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 89, 4325–4330.
- Janes CH Dickson ER Okazaki A et al. (1995) Role of hyperbilirubi-naemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 95, 2581–2586.
- Pereira SP O'Donohue J Moniz CP et al. (2004) Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. Aliment Pharmacol Ther 19, 563–570.
- Ormarsdottir S Mallmin H Naessen T et al. (2004) An open randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med 256, 63–69.
- Ettinger B Black DM Mitlak BH et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282, 637–645.
- Meunier PJ Roux C Seeman E et al. (2004) The effect of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350, 459–468.
- Guideline Development Group for the Bone and Tooth Society National Osteoporosis Society and Royal College of Physicians (2002) Glucocorticoid-induced Osteoporosis. Guidelines for Prevention and Treatment. London: Royal College of Physicians.
- Compston J (2003) Osteoporosis after liver transplantation. Liver Transpl 9, 321–330.
- Ninkovic M Love S Tom BDM et al. (2002) Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 37, 93–100.
- Vedi S Greer S Skingle SJ et al. (1999) Mechanism of bone loss after liver transplantation: a histomorphometric analysis. J Bone Min Res 14, 281–287.
- Compston J (2003) The skeletal effects of liver transplantation in children. Liver Transpl 9, 371–372.
- Herlong HF Recker RR Maddrey WC (1982) Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 83, 103–108.
- Kobayashi A Kawai S Utsunomiya T et al. (1974) Bone disease in infants and children with hepatobiliary disease. Arch Dis Child 49, 641–646.
- Long RG Skinner RK Wills MR et al. (1976) Serum 25-hydroxyvitamin D in untreated parenchymal and cholestatic liver disease. Lancet ii, 650–652.
-
Compston JE
Thompson RPH
(1977)
Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis.
Lancet
i,
721–724.
10.1016/S0140-6736(77)92167-5 Google Scholar
